[Retracted] Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Carcinoma: A Real-World Study

Table 2

Predictive factors of pCR according to the multivariate logistic regression model.

	Univariate			Multivariate
	OR	95% CI	value	OR	95% CI	value
Age (year)			0.193			0.189
≤35	1.000			1.000
>35	2.286	0.659–7.931		2.438	0.645–9.209
Menopausal status			0.527			0.727
Premenopausal	1.000			1.000
Postmenopausal	1.225	0.652–2.303		1.130	0.570–2.237
cT stage			0.39			0.900
cT1–2	1.000			1.000
cT3–4	0.734	0.363–1.485		0.951	0.436–2.075
cN stage			0.073			0.324
cN0	1.000			1.000
cN1–3	0.549	0.285–1.057		0.698	0.342–1.425
Grade			0.729			0.453
G1–2	1.000			1.000
G3	0.878	0.420–1.836		0.738	0.334–1.631
ER			0.473			0.311
Positive	1.000			1.000
Negative	1.260	0.670–2.368		2.415	0.439–13.279
PR			0.949			0.931
Positive	1.000			1.000
Negative	1.021	00.542–1.922		0.886	0.057–13.698
HR			0.854			0.906
Positive	1.000			1.000
Negative	1.061	0.562–2.005		0.843	0.050–14.302
Ki-67			0.791			0.884
>30%	1.000			1.000
≤30%	1.090	0.579–2.051		1.051	0.538–2.054
Molecular subtype			0.607			0.590
Luminal B/HER2+	1.000			1.000
Nonluminal/HER2+	1.180	0.628–2.216		0.610	0.101–3.678
Trastuzumab			0.005			0.004
Yes	1.000			1.000
No	0.397	0.209–0.754		0.361	0.180–0.725